Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $115 from $130 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and telling investors to remain patient through the tariffs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Cautious Hold on Zimmer Biomet Amid Mixed Performance and Strategic Adjustments
- Zimmer Biomet price target lowered to $110 from $135 at BofA
- Zimmer Biomet price target lowered to $115 from $138 at Stifel
- Cautious Outlook for Zimmer Biomet Holdings Amid Tariff Exposure and Conservative Guidance
- Zimmer Biomet Reports Q1 2025 Financial Results